Short Interest in Tharimmune, Inc. (NASDAQ:THAR) Expands By 68.8%

Tharimmune, Inc. (NASDAQ:THAR) saw a large growth in short interest in the month of June. As of June 15th, there was short interest totalling 26,000 shares, a growth of 68.8% from the May 31st total of 15,400 shares. Based on an average daily volume of 43,100 shares, the days-to-cover ratio is currently 0.6 days. Currently, 3.4% of the company’s shares are sold short.

Tharimmune Trading Up 9.3 %

THAR traded up $0.30 during trading on Friday, hitting $3.53. 66,986 shares of the stock were exchanged, compared to its average volume of 90,199. The firm has a 50 day simple moving average of $4.69 and a 200 day simple moving average of $5.84. Tharimmune has a 1 year low of $2.75 and a 1 year high of $163.09.

Tharimmune (NASDAQ:THAR) last released its quarterly earnings data on Thursday, May 9th. The company reported ($2.85) EPS for the quarter.

About Tharimmune

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).